AADAC | Arylacetamide deacetylase | Enzymes
| | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
AC012215.1 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AC021218.2 | Uncharacterized protein | | | | | | Tissue enhanced |
AC079602.1 | | | | | | | Tissue enhanced |
AC138517.1 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACER2 | Alkaline ceramidase 2 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes
| | | | | Tissue enhanced |
ADAM28 | ADAM metallopeptidase domain 28 | Enzymes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADAMDEC1 | ADAM-like, decysin 1 | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ADTRP | Androgen-dependent TFPI-regulating protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
AKR7A3 | Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) | | | | | | Tissue enhanced |
AL354898.1 | | | | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ANKRD22 | Ankyrin repeat domain 22 | | | | | | Tissue enhanced |
ANKS4B | Ankyrin repeat and sterile alpha motif domain containing 4B | | | | | | Tissue enhanced |
ANO9 | Anoctamin 9 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
AQP11 | Aquaporin 11 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | | | | | | Tissue enhanced |
ASAH2B | N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B | | | | | | Tissue enhanced |
ASIC5 | Acid-sensing (proton-gated) ion channel family member 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
ATP10B | ATPase, class V, type 10B | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
B3GALT1 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT6 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (core 3 synthase) | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
BAIAP2L2 | BAI1-associated protein 2-like 2 | | | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | | | | | | Tissue enhanced |
BCMO1 | Beta-carotene 15,15'-monooxygenase 1 | Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
BRINP3 | Bone morphogenetic protein/retinoic acid inducible neural-specific 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
C10orf129 | Chromosome 10 open reading frame 129 | Enzymes Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
C19orf77 | Chromosome 19 open reading frame 77 | Predicted membrane proteins
| | | | | Tissue enhanced |
C1orf106 | Chromosome 1 open reading frame 106 | | | | | | Tissue enhanced |
C6orf222 | Chromosome 6 open reading frame 222 | | | | | | Tissue enhanced |
C9orf152 | Chromosome 9 open reading frame 152 | | | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA7 | Carbonic anhydrase VII | Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |